Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis
- 430 Downloads
Background Target trough concentrations are recommended for teicoplanin (TEIC) to minimize its adverse effects and to maximize efficacy in sepsis caused by grampositive cocci, including methicillin-resistant Staphylococcus aureus infection. However, optimal doses to attain proper trough values in patients with sepsis have not yet been well established for TEIC. Objective This study investigated whether the systemic inflammatory response syndrome (SIRS) score could predict the pharmacokinetics of TEIC in patients with sepsis. Setting This study was conducted at Fukuoka University Hospital in Japan. Methods We retrospectively reviewed the records of patients using TEIC between April 2012 and March 2015. SIRS positive was defined as infection with a SIRS score ≥2. Estimates of pharmacokinetic parameters were calculated using a Bayesian method. Creatinine clearance rates were estimated by the Cockcroft–Gault formula (eCcr). Main outcome measure Change of TEIC loading dose requirement for incremental increases of SIRS score. Results In total, 133 patients were enrolled: 50 non-SIRS patients and 83 patients with SIRS. The TEIC plasma trough concentration was significantly lower in SIRS than non-SIRS patients (15.7 ± 7.1 vs. 20.1 ± 8.6 μg/mL; P < 0.01), although there was no significant difference in the loading dose administered. Moreover, SIRS scores were increasingly predictive of eCcr and TEIC clearance in a stepwise manner. To achieve the target trough concentration (15–30 μg/mL), the optimal doses required in non-SIRS versus SIRS patients were 12–24 versus 18–30 mg/kg/day, respectively, during the first 48 h. Conclusions These findings suggest that the pharmacokinetics of TEIC are altered in SIRS patients, who required higher doses than non-SIRS patients to achieve the target trough concentration. We suggest that the SIRS score can become a new modality to determine the initial TEIC loading dose.
KeywordsInflammatory response Pharmacokinetics Severe sepsis Systemic inflammatory response syndrome Teicoplanin
Conflicts of interest
The authors declare that there are no conflicts of interest.
- 1.Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55.CrossRefPubMedGoogle Scholar
- 6.Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations. Int J Antimicrob Agents. 2007;29:322–5.CrossRefPubMedGoogle Scholar
- 9.The Japanese Association for Infectious Diseases, the Japanese Society of Chemotherapy. The JAID/JSC guide to clinical management of infectious diseases. Tokyo: Sanposha Printing; 2014.Google Scholar
- 14.The Japanese Society of Chemotherapy, the Japanese Society of Therapeutic Drug Monitoring. Clinical practice guidelines for TDM of antimicrobial agents. Tokyo: Kyorinsha; 2012.Google Scholar
- 16.Mitsuda M, Noguchi K, Kosako K, Tsuji N, Nogiwa T, Matsubara F, et al. Clinical efficacy of teicoplanin with high-dose loading regimen for MRSA infection. Jpn J TDM. 2009;26:14–20.Google Scholar
- 18.Nakano T, Nakamura Y, Togawa A, Takata T, Ishikura H, Mishima K, et al. Necessity of personalized initial loading dose calculation of teicoplanin by clinical pharmacist-examination of the utility of using systemic inflammatory response syndrome score. Yakugaku Zasshi. 2014;134:1367–73.CrossRefPubMedGoogle Scholar
- 20.Nakayama K, Gemma H, Kaibara A, Niwa T. Population pharmacokinetics of teicoplanin in adult patients. Jpn J Chemother. 2006;54:1–6.Google Scholar
- 33.Brink AJ, Richards GA, Cummins RR, Lambson J, Gauteng Understanding Teicoplanin Serum levels (GUTS) Study Group. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalized patients treated for sepsis. Int J Antimicrob Agents. 2008;32:455–8.CrossRefPubMedGoogle Scholar